#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-10	Attenuated	_
1-2	11-17	neural	_
1-3	18-26	response	_
1-4	27-29	to	_
1-5	30-39	emotional	_
1-6	40-44	cues	_
1-7	45-47	in	_
1-8	48-66	cocaine-dependence	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-9	67-68	:	_
1-10	69-70	a	_
1-11	71-82	preliminary	_
1-12	83-91	analysis	_
1-13	92-94	of	_
1-14	95-101	gender	_
1-15	102-113	differences	_
1-16	114-124	Background	_
1-17	125-132	Cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-18	133-138	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-19	139-144	often	_
1-20	145-151	report	_
1-21	152-153	a	_
1-22	154-158	loss	_
1-23	159-161	of	_
1-24	162-169	arousal	_
1-25	170-173	for	_
1-26	174-189	nondrug-related	_
1-27	190-197	stimuli	_
1-28	198-199	,	_
1-29	200-205	which	_
1-30	206-209	may	_
1-31	210-220	contribute	_
1-32	221-223	to	_
1-33	224-229	their	_
1-34	230-238	response	_
1-35	239-241	to	_
1-36	242-254	drug-related	_
1-37	255-262	rewards	_
1-38	263-264	.	_

2-1	265-272	However	_
2-2	273-274	,	_
2-3	275-281	little	_
2-4	282-284	is	_
2-5	285-290	known	_
2-6	291-296	about	_
2-7	297-302	users	_
2-8	303-304	â€™	_
2-9	305-311	neural	_
2-10	312-322	reactivity	_
2-11	323-325	to	_
2-12	326-335	emotional	_
2-13	336-351	nondrug-related	_
2-14	352-359	stimuli	_
2-15	360-363	and	_
2-16	364-367	the	_
2-17	368-377	potential	_
2-18	378-387	influence	_
2-19	388-390	of	_
2-20	391-397	gender	_
2-21	398-399	.	_

3-1	400-410	Objectives	_
3-2	411-415	Test	_
3-3	416-419	the	_
3-4	420-430	hypotheses	_
3-5	431-435	that	_
3-6	436-453	cocaine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-7	454-465	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-8	466-470	have	_
3-9	471-473	an	_
3-10	474-484	attenuated	_
3-11	485-491	neural	_
3-12	492-500	response	_
3-13	501-503	to	_
3-14	504-512	arousing	_
3-15	513-520	stimuli	_
3-16	521-529	relative	_
3-17	530-532	to	_
3-18	533-541	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-19	542-545	and	_
3-20	546-550	that	_
3-21	551-555	this	_
3-22	556-566	difference	_
3-23	567-569	is	_
3-24	570-579	amplified	_
3-25	580-582	in	_
3-26	583-588	women	_
3-27	589-590	.	_

4-1	591-598	Methods	_
4-2	599-602	The	_
4-3	603-608	brain	_
4-4	609-617	response	_
4-5	618-620	to	_
4-6	621-630	typically	_
4-7	631-639	arousing	_
4-8	640-648	positive	_
4-9	649-652	and	_
4-10	653-661	negative	_
4-11	662-668	images	_
4-12	669-671	as	_
4-13	672-676	well	_
4-14	677-679	as	_
4-15	680-687	neutral	_
4-16	688-694	images	_
4-17	695-699	from	_
4-18	700-703	the	_
4-19	704-717	International	_
4-20	718-727	Affective	_
4-21	728-735	Picture	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
4-22	736-742	System	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
4-23	743-746	was	_
4-24	747-755	measured	_
4-25	756-758	in	_
4-26	759-761	40	_
4-27	762-773	individuals	_
4-28	774-775	(	_
4-29	776-778	20	_
4-30	779-792	non-treatment	_
4-31	793-800	seeking	_
4-32	801-818	cocaine-dependent	_
4-33	819-822	and	_
4-34	823-825	20	_
4-35	826-830	age-	_
4-36	831-834	and	_
4-37	835-849	gender-matched	_
4-38	850-857	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
4-39	858-870	participants	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
4-40	871-872	;	_
4-41	873-875	50	_
4-42	876-877	%	_
4-43	878-880	of	_
4-44	881-885	whom	_
4-45	886-890	were	_
4-46	891-896	women	_
4-47	897-898	)	_
4-48	899-900	.	_

5-1	901-907	Images	_
5-2	908-912	were	_
5-3	913-922	displayed	_
5-4	923-926	for	_
5-5	927-928	4	_
5-6	929-930	s	_
5-7	931-935	each	_
5-8	936-938	in	_
5-9	939-945	blocks	_
5-10	946-948	of	_
5-11	949-953	five	_
5-12	954-960	across	_
5-13	961-964	two	_
5-14	965-975	270-second	_
5-15	976-980	runs	_
5-16	981-982	.	_

6-1	983-990	General	_
6-2	991-997	linear	_
6-3	998-1004	models	_
6-4	1005-1013	assessed	_
6-5	1014-1020	within	_
6-6	1021-1024	and	_
6-7	1025-1032	between	_
6-8	1033-1038	group	_
6-9	1039-1049	activation	_
6-10	1050-1061	differences	_
6-11	1062-1065	for	_
6-12	1066-1069	the	_
6-13	1070-1079	emotional	_
6-14	1080-1086	images	_
6-15	1087-1088	.	_

7-1	1089-1096	Results	_
7-2	1097-1114	Cocaine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
7-3	1115-1126	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
7-4	1127-1130	had	_
7-5	1131-1132	a	_
7-6	1133-1146	significantly	_
7-7	1147-1152	lower	_
7-8	1153-1161	response	_
7-9	1162-1164	to	_
7-10	1165-1174	typically	_
7-11	1175-1183	arousing	_
7-12	1184-1192	positive	_
7-13	1193-1196	and	_
7-14	1197-1205	negative	_
7-15	1206-1212	images	_
7-16	1213-1217	than	_
7-17	1218-1226	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-18	1227-1228	,	_
7-19	1229-1233	with	_
7-20	1234-1244	attenuated	_
7-21	1245-1251	neural	_
7-22	1252-1260	activity	_
7-23	1261-1268	present	_
7-24	1269-1271	in	_
7-25	1272-1275	the	_
7-26	1276-1282	medial	_
7-27	1283-1293	prefrontal	_
7-28	1294-1300	cortex	_
7-29	1301-1302	(	_
7-30	1303-1307	mPFC	_
7-31	1308-1309	)	_
7-32	1310-1313	and	_
7-33	1314-1322	anterior	_
7-34	1323-1332	cingulate	_
7-35	1333-1339	cortex	_
7-36	1340-1341	(	_
7-37	1342-1345	ACC	_
7-38	1346-1347	)	_
7-39	1348-1349	.	_

8-1	1350-1358	Analyses	_
8-2	1359-1361	by	_
8-3	1362-1368	gender	_
8-4	1369-1377	revealed	_
8-5	1378-1382	less	_
8-6	1383-1391	mPFC/ACC	_
8-7	1392-1402	activation	_
8-8	1403-1408	among	_
8-9	1409-1415	female	_
8-10	1416-1421	users	_
8-11	1422-1423	,	_
8-12	1424-1427	but	_
8-13	1428-1431	not	_
8-14	1432-1437	males	_
8-15	1438-1439	,	_
8-16	1440-1443	for	_
8-17	1444-1448	both	_
8-18	1449-1457	positive	_
8-19	1458-1461	and	_
8-20	1462-1470	negative	_
8-21	1471-1477	images	_
8-22	1478-1479	.	_

9-1	1480-1490	Conclusion	_
9-2	1491-1494	The	_
9-3	1495-1503	dampened	_
9-4	1504-1510	neural	_
9-5	1511-1519	response	_
9-6	1520-1522	to	_
9-7	1523-1532	typically	_
9-8	1533-1541	arousing	_
9-9	1542-1549	stimuli	_
9-10	1550-1555	among	_
9-11	1556-1573	cocaine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
9-12	1574-1582	polydrug	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
9-13	1583-1588	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
9-14	1589-1597	suggests	_
9-15	1598-1607	decreased	_
9-16	1608-1616	salience	_
9-17	1617-1627	processing	_
9-18	1628-1631	for	_
9-19	1632-1639	nondrug	_
9-20	1640-1647	stimuli	_
9-21	1648-1649	,	_
9-22	1650-1662	particularly	_
9-23	1663-1668	among	_
9-24	1669-1675	female	_
9-25	1676-1681	users	_
9-26	1682-1683	.	_

10-1	1684-1688	This	_
10-2	1689-1698	decreased	_
10-3	1699-1709	responding	_
10-4	1710-1712	is	_
10-5	1713-1723	consistent	_
10-6	1724-1728	with	_
10-7	1729-1733	data	_
10-8	1734-1738	from	_
10-9	1739-1744	other	_
10-10	1745-1754	substance	_
10-11	1755-1760	using	_
10-12	1761-1772	populations	_
10-13	1773-1776	and	_
10-14	1777-1785	suggests	_
10-15	1786-1790	that	_
10-16	1791-1795	this	_
10-17	1796-1799	may	_
10-18	1800-1802	be	_
10-19	1803-1804	a	_
10-20	1805-1812	general	_
10-21	1813-1820	feature	_
10-22	1821-1823	of	_
10-23	1824-1833	addiction	_
10-24	1834-1835	.	_

11-1	1836-1846	Amplifying	_
11-2	1847-1850	the	_
11-3	1851-1857	neural	_
11-4	1858-1866	response	_
11-5	1867-1869	to	_
11-6	1870-1879	naturally	_
11-7	1880-1888	arousing	_
11-8	1889-1904	nondrug-related	_
11-9	1905-1916	reinforcers	_
11-10	1917-1920	may	_
11-11	1921-1928	present	_
11-12	1929-1931	an	_
11-13	1932-1943	opportunity	_
11-14	1944-1947	for	_
11-15	1948-1954	unique	_
11-16	1955-1965	behavioral	_
11-17	1966-1969	and	_
11-18	1970-1975	brain	_
11-19	1976-1987	stimulation	_
11-20	1988-1997	therapies	_
11-21	1998-1999	.	_

12-1	2000-2007	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
12-2	2008-2020	Participants	_
12-3	2021-2024	The	_
12-4	2025-2030	study	_
12-5	2031-2034	was	_
12-6	2035-2043	approved	_
12-7	2044-2046	by	_
12-8	2047-2050	the	_
12-9	2051-2064	Institutional	_
12-10	2065-2071	Review	_
12-11	2072-2077	Board	_
12-12	2078-2081	and	_
12-13	2082-2085	all	_
12-14	2086-2098	participants	_
12-15	2099-2107	provided	_
12-16	2108-2115	written	_
12-17	2116-2124	informed	_
12-18	2125-2132	consent	_
12-19	2133-2134	.	_

13-1	2135-2140	Forty	_
13-2	2141-2152	individuals	_
13-3	2153-2162	completed	_
13-4	2163-2167	this	_
13-5	2168-2173	study	_
13-6	2174-2177	and	_
13-7	2178-2182	were	_
13-8	2183-2190	entered	_
13-9	2191-2195	into	_
13-10	2196-2199	the	_
13-11	2200-2205	final	_
13-12	2206-2210	data	_
13-13	2211-2219	analysis	_
13-14	2220-2221	:	_
13-15	2222-2224	20	_
13-16	2225-2238	non-treatment	_
13-17	2239-2246	seeking	_
13-18	2247-2264	cocaine-dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
13-19	2265-2276	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
13-20	2277-2280	and	_
13-21	2281-2283	20	_
13-22	2284-2295	individuals	_
13-23	2296-2300	with	_
13-24	2301-2303	no	_
13-25	2304-2312	lifetime	_
13-26	2313-2320	history	_
13-27	2321-2323	of	_
13-28	2324-2328	drug	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineDependence
13-29	2329-2331	or	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineDependence
13-30	2332-2339	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineDependence
13-31	2340-2350	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AmphetamineDependence
13-32	2351-2352	(	_
13-33	2353-2356	see	_
13-34	2357-2370	Supplementary	_
13-35	2371-2379	Material	_
13-36	2380-2383	for	_
13-37	2384-2388	more	_
13-38	2389-2396	details	_
13-39	2397-2399	in	_
13-40	2400-2409	exclusion	_
13-41	2410-2418	criteria	_
13-42	2419-2420	)	_
13-43	2421-2422	.	_

14-1	2423-2426	The	_
14-2	2427-2431	mean	_
14-3	2432-2435	age	_
14-4	2436-2439	was	_
14-5	2440-2445	35.55	_
14-6	2446-2449	for	_
14-7	2450-2454	drug	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
14-8	2455-2460	users	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
14-9	2461-2464	and	_
14-10	2465-2470	34.85	_
14-11	2471-2474	for	_
14-12	2475-2483	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-13	2484-2485	,	_
14-14	2486-2489	and	_
14-15	2490-2492	it	_
14-16	2493-2496	did	_
14-17	2497-2500	not	_
14-18	2501-2507	differ	_
14-19	2508-2510	by	_
14-20	2511-2515	user	_
14-21	2516-2522	status	_
14-22	2523-2525	or	_
14-23	2526-2532	gender	_
14-24	2533-2534	.	_

15-1	2535-2538	The	_
15-2	2539-2546	control	_
15-3	2547-2552	group	_
15-4	2553-2556	had	_
15-5	2557-2561	less	_
15-6	2562-2571	cigarette	_
15-7	2572-2579	smokers	_
15-8	2580-2581	(	_
15-9	2582-2590	controls	_
15-10	2591-2592	=	_
15-11	2593-2594	3	_
15-12	2595-2596	,	_
15-13	2597-2602	users	_
15-14	2603-2604	=	_
15-15	2605-2607	17	_
15-16	2608-2609	,	_
15-17	2610-2611	p	_
15-18	2612-2613	<	_
15-19	2614-2617	.05	_
15-20	2618-2619	)	_
15-21	2620-2621	,	_
15-22	2622-2626	more	_
15-23	2627-2632	years	_
15-24	2633-2635	of	_
15-25	2636-2645	education	_
15-26	2646-2647	(	_
15-27	2648-2656	controls	_
15-28	2657-2658	=	_
15-29	2659-2664	16.15	_
15-30	2665-2666	,	_
15-31	2667-2672	users	_
15-32	2673-2674	=	_
15-33	2675-2680	12.85	_
15-34	2681-2682	;	_
15-35	2683-2684	t	_
15-36	2685-2686	=	_
15-37	2687-2691	4.20	_
15-38	2692-2693	,	_
15-39	2694-2695	p	_
15-40	2696-2697	<	_
15-41	2698-2702	.001	_
15-42	2703-2704	)	_
15-43	2705-2706	,	_
15-44	2707-2712	lower	_
15-45	2713-2719	BDI-II	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
15-46	2720-2726	scores	_
15-47	2727-2728	(	_
15-48	2729-2737	controls	_
15-49	2738-2739	=	_
15-50	2740-2743	.85	_
15-51	2744-2745	,	_
15-52	2746-2751	users	_
15-53	2752-2753	=	_
15-54	2754-2758	5.75	_
15-55	2759-2760	;	_
15-56	2761-2762	t	_
15-57	2763-2764	=	_
15-58	2765-2769	3.89	_
15-59	2770-2771	,	_
15-60	2772-2773	p	_
15-61	2774-2775	<	_
15-62	2776-2779	.01	_
15-63	2780-2781	)	_
15-64	2782-2783	,	_
15-65	2784-2787	and	_
15-66	2788-2793	lower	_
15-67	2794-2799	state	_
15-68	2800-2807	anxiety	_
15-69	2808-2809	(	_
15-70	2810-2818	controls	_
15-71	2819-2820	=	_
15-72	2821-2825	21.8	_
15-73	2826-2827	,	_
15-74	2828-2833	users	_
15-75	2834-2835	=	_
15-76	2836-2840	28.6	_
15-77	2841-2842	,	_
15-78	2843-2844	t	_
15-79	2845-2846	=	_
15-80	2847-2851	3.19	_
15-81	2852-2853	,	_
15-82	2854-2855	p	_
15-83	2856-2857	<	_
15-84	2858-2861	.01	_
15-85	2862-2863	)	_
15-86	2864-2868	than	_
15-87	2869-2872	the	_
15-88	2873-2877	user	_
15-89	2878-2883	group	_
15-90	2884-2885	.	_

16-1	2886-2891	There	_
16-2	2892-2896	were	_
16-3	2897-2899	no	_
16-4	2900-2911	significant	_
16-5	2912-2918	gender	_
16-6	2919-2930	differences	_
16-7	2931-2938	between	_
16-8	2939-2943	each	_
16-9	2944-2949	group	_
16-10	2950-2951	.	_

17-1	2952-2955	See	_
17-2	2956-2961	Table	_
17-3	2962-2963	1	_
17-4	2964-2967	for	_
17-5	2968-2977	breakdown	_
17-6	2978-2980	by	_
17-7	2981-2987	gender	_
17-8	2988-2991	and	_
17-9	2992-2996	user	_
17-10	2997-3002	group	_
17-11	3003-3004	.	_

18-1	3005-3012	Cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
18-2	3013-3018	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
18-3	3019-3022	had	_
18-4	3023-3024	a	_
18-5	3025-3029	mean	_
18-6	3030-3033	age	_
18-7	3034-3036	of	_
18-8	3037-3042	first	_
18-9	3043-3046	use	_
18-10	3047-3049	of	_
18-11	3050-3055	20.05	_
18-12	3056-3057	(	_
18-13	3058-3060	SD	_
18-14	3061-3062	=	_
18-15	3063-3067	3.50	_
18-16	3068-3069	)	_
18-17	3070-3075	years	_
18-18	3076-3079	old	_
18-19	3080-3083	and	_
18-20	3084-3087	had	_
18-21	3088-3092	been	_
18-22	3093-3098	using	_
18-23	3099-3102	for	_
18-24	3103-3104	a	_
18-25	3105-3109	mean	_
18-26	3110-3112	of	_
18-27	3113-3117	15.5	_
18-28	3118-3119	(	_
18-29	3120-3122	SD	_
18-30	3123-3124	=	_
18-31	3125-3129	8.02	_
18-32	3130-3131	)	_
18-33	3132-3137	years	_
18-34	3138-3139	,	_
18-35	3140-3143	and	_
18-36	3144-3147	did	_
18-37	3148-3151	not	_
18-38	3152-3158	differ	_
18-39	3159-3161	by	_
18-40	3162-3168	gender	_
18-41	3169-3170	.	_

19-1	3171-3180	Procedure	_
19-2	3181-3187	During	_
19-3	3188-3191	the	_
19-4	3192-3196	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
19-5	3197-3205	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
19-6	3206-3213	session	_
19-7	3214-3215	,	_
19-8	3216-3228	participants	_
19-9	3229-3233	were	_
19-10	3234-3243	presented	_
19-11	3244-3248	with	_
19-12	3249-3255	blocks	_
19-13	3256-3258	of	_
19-14	3259-3265	highly	_
19-15	3266-3274	arousing	_
19-16	3275-3283	positive	_
19-17	3284-3287	and	_
19-18	3288-3296	negative	_
19-19	3297-3300	and	_
19-20	3301-3312	emotionally	_
19-21	3313-3320	neutral	_
19-22	3321-3333	standardized	_
19-23	3334-3340	images	_
19-24	3341-3349	selected	_
19-25	3350-3354	from	_
19-26	3355-3358	the	_
19-27	3359-3372	International	_
19-28	3373-3382	Affective	_
19-29	3383-3390	Picture	_
19-30	3391-3397	System	_
19-31	3398-3399	.	_

20-1	3400-3403	The	_
20-2	3404-3411	stimuli	_
20-3	3412-3420	included	_
20-4	3421-3422	:	_
20-5	3423-3425	30	_
20-6	3426-3434	positive	_
20-7	3435-3436	(	_
20-8	3437-3444	valence	_
20-9	3445-3446	M	_
20-10	3447-3448	=	_
20-11	3449-3453	6.87	_
20-12	3454-3455	,	_
20-13	3456-3458	SD	_
20-14	3459-3460	=	_
20-15	3461-3464	.52	_
20-16	3465-3466	)	_
20-17	3467-3468	,	_
20-18	3469-3471	30	_
20-19	3472-3480	negative	_
20-20	3481-3482	(	_
20-21	3483-3490	valence	_
20-22	3491-3492	M	_
20-23	3493-3494	=	_
20-24	3495-3499	2.27	_
20-25	3500-3501	,	_
20-26	3502-3504	SD	_
20-27	3505-3506	=	_
20-28	3507-3510	.52	_
20-29	3511-3512	)	_
20-30	3513-3514	,	_
20-31	3515-3518	and	_
20-32	3519-3521	30	_
20-33	3522-3529	neutral	_
20-34	3530-3536	images	_
20-35	3537-3538	(	_
20-36	3539-3546	valence	_
20-37	3547-3548	M	_
20-38	3549-3550	=	_
20-39	3551-3555	4.91	_
20-40	3556-3557	,	_
20-41	3558-3560	SD	_
20-42	3561-3562	=	_
20-43	3563-3566	.67	_
20-44	3567-3568	)	_
20-45	3569-3570	.	_

21-1	3571-3583	Participants	_
21-2	3584-3593	passively	_
21-3	3594-3600	viewed	_
21-4	3601-3604	the	_
21-5	3605-3611	images	_
21-6	3612-3615	and	_
21-7	3616-3620	were	_
21-8	3621-3631	instructed	_
21-9	3632-3634	to	_
21-10	3635-3640	allow	_
21-11	3641-3651	themselves	_
21-12	3652-3654	to	_
21-13	3655-3659	feel	_
21-14	3660-3668	whatever	_
21-15	3669-3674	comes	_
21-16	3675-3684	naturally	_
21-17	3685-3689	when	_
21-18	3690-3697	viewing	_
21-19	3698-3701	the	_
21-20	3702-3710	pictures	_
21-21	3711-3712	.	_

22-1	3713-3720	Because	_
22-2	3721-3723	of	_
22-3	3724-3727	the	_
22-4	3728-3736	interest	_
22-5	3737-3739	in	_
22-6	3740-3749	comparing	_
22-7	3750-3761	alterations	_
22-8	3762-3764	in	_
22-9	3765-3774	emotional	_
22-10	3775-3783	response	_
22-11	3784-3789	among	_
22-12	3790-3794	male	_
22-13	3795-3798	and	_
22-14	3799-3805	female	_
22-15	3806-3813	cocaine	_
22-16	3814-3819	users	_
22-17	3820-3821	,	_
22-18	3822-3828	images	_
22-19	3829-3833	were	_
22-20	3834-3842	selected	_
22-21	3843-3845	to	_
22-22	3846-3848	be	_
22-23	3849-3856	matched	_
22-24	3857-3859	on	_
22-25	3860-3867	arousal	_
22-26	3868-3874	within	_
22-27	3875-3879	each	_
22-28	3880-3885	block	_
22-29	3886-3891	among	_
22-30	3892-3895	men	_
22-31	3896-3899	and	_
22-32	3900-3905	women	_
22-33	3906-3911	based	_
22-34	3912-3914	on	_
22-35	3915-3927	standardized	_
22-36	3928-3934	scores	_
22-37	3935-3936	(	_
22-38	3937-3939	no	_
22-39	3940-3951	significant	_
22-40	3952-3958	gender	_
22-41	3959-3969	difference	_
22-42	3970-3971	)	_
22-43	3972-3973	.	_

23-1	3974-3981	Arousal	_
23-2	3982-3989	ratings	_
23-3	3990-3992	by	_
23-4	3993-3999	gender	_
23-5	4000-4003	and	_
23-6	4004-4006	by	_
23-7	4007-4016	condition	_
23-8	4017-4021	were	_
23-9	4022-4024	as	_
23-10	4025-4032	follows	_
23-11	4033-4034	:	_
23-12	4035-4043	positive	_
23-13	4044-4045	(	_
23-14	4046-4049	men	_
23-15	4050-4051	M	_
23-16	4052-4053	=	_
23-17	4054-4058	6.15	_
23-18	4059-4060	,	_
23-19	4061-4063	SD	_
23-20	4064-4065	=	_
23-21	4066-4069	.67	_
23-22	4070-4071	;	_
23-23	4072-4077	women	_
23-24	4078-4079	:	_
23-25	4080-4081	M	_
23-26	4082-4083	=	_
23-27	4084-4088	5.94	_
23-28	4089-4090	,	_
23-29	4091-4093	SD	_
23-30	4094-4095	=	_
23-31	4096-4099	.39	_
23-32	4100-4101	)	_
23-33	4102-4103	;	_
23-34	4104-4112	negative	_
23-35	4113-4114	(	_
23-36	4115-4118	men	_
23-37	4119-4120	:	_
23-38	4121-4122	M	_
23-39	4123-4124	=	_
23-40	4125-4129	5.97	_
23-41	4130-4131	,	_
23-42	4132-4134	SD	_
23-43	4135-4136	=	_
23-44	4137-4140	.60	_
23-45	4141-4142	;	_
23-46	4143-4148	women	_
23-47	4149-4150	:	_
23-48	4151-4152	M	_
23-49	4153-4154	=	_
23-50	4155-4159	6.42	_
23-51	4160-4161	,	_
23-52	4162-4164	SD	_
23-53	4165-4166	=	_
23-54	4167-4170	.68	_
23-55	4171-4172	)	_
23-56	4173-4174	;	_
23-57	4175-4178	and	_
23-58	4179-4186	neutral	_
23-59	4187-4188	(	_
23-60	4189-4192	men	_
23-61	4193-4194	:	_
23-62	4195-4196	M	_
23-63	4197-4198	=	_
23-64	4199-4203	3.50	_
23-65	4204-4205	,	_
23-66	4206-4208	SD	_
23-67	4209-4210	=	_
23-68	4211-4214	.63	_
23-69	4215-4216	;	_
23-70	4217-4222	women	_
23-71	4223-4224	:	_
23-72	4225-4226	M	_
23-73	4227-4228	=	_
23-74	4229-4233	3.45	_
23-75	4234-4235	,	_
23-76	4236-4238	SD	_
23-77	4239-4240	=	_
23-78	4241-4244	.66	_
23-79	4245-4246	)	_
23-80	4247-4248	.	_

24-1	4249-4251	To	_
24-2	4252-4259	control	_
24-3	4260-4263	for	_
24-4	4264-4273	potential	_
24-5	4274-4285	differences	_
24-6	4286-4288	in	_
24-7	4289-4295	social	_
24-8	4296-4306	responding	_
24-9	4307-4312	among	_
24-10	4313-4323	conditions	_
24-11	4324-4325	,	_
24-12	4326-4329	all	_
24-13	4330-4336	images	_
24-14	4337-4346	contained	_
24-15	4347-4349	at	_
24-16	4350-4355	least	_
24-17	4356-4359	one	_
24-18	4360-4366	person	_
24-19	4367-4368	,	_
24-20	4369-4372	and	_
24-21	4373-4377	each	_
24-22	4378-4386	category	_
24-23	4387-4389	of	_
24-24	4390-4396	images	_
24-25	4397-4406	contained	_
24-26	4407-4418	individuals	_
24-27	4419-4423	from	_
24-28	4424-4433	different	_
24-29	4434-4440	racial	_
24-30	4441-4444	and	_
24-31	4445-4451	ethnic	_
24-32	4452-4463	backgrounds	_
24-33	4464-4465	.	_

25-1	4466-4472	Images	_
25-2	4473-4477	were	_
25-3	4478-4487	presented	_
25-4	4488-4490	in	_
25-5	4491-4494	two	_
25-6	4495-4505	functional	_
25-7	4506-4510	runs	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
25-8	4511-4518	lasting	_
25-9	4519-4523	270s	_
25-10	4524-4528	each	_
25-11	4529-4530	.	_

26-1	4531-4535	Each	http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria
26-2	4536-4539	run	http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria
26-3	4540-4549	consisted	http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria
26-4	4550-4552	of	http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria
26-5	4553-4557	nine	http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria
26-6	4558-4561	20s	http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria
26-7	4562-4568	blocks	http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria
26-8	4569-4570	:	http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria
26-9	4571-4576	three	http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria
26-10	4577-4581	each	http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria
26-11	4582-4584	of	http://maven.renci.org/NeuroBridge/neurobridge#CAARMSPsychosisThresholdCriteria
26-12	4585-4593	positive	_
26-13	4594-4595	,	_
26-14	4596-4604	negative	_
26-15	4605-4606	,	_
26-16	4607-4610	and	_
26-17	4611-4618	neutral	_
26-18	4619-4625	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
26-19	4626-4627	.	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol

27-1	4628-4632	Each	_
27-2	4633-4642	affective	_
27-3	4643-4648	block	_
27-4	4649-4658	contained	_
27-5	4659-4663	five	_
27-6	4664-4670	images	_
27-7	4671-4680	presented	_
27-8	4681-4684	for	_
27-9	4685-4686	4	_
27-10	4687-4688	s	_
27-11	4689-4693	each	_
27-12	4694-4695	.	_

28-1	4696-4700	Each	_
28-2	4701-4706	image	_
28-3	4707-4712	block	_
28-4	4713-4716	was	_
28-5	4717-4726	separated	_
28-6	4727-4729	by	_
28-7	4730-4731	a	_
28-8	4732-4736	10-s	_
28-9	4737-4741	rest	_
28-10	4742-4747	block	_
28-11	4748-4749	(	_
28-12	4750-4755	cross	_
28-13	4756-4760	hair	_
28-14	4761-4762	)	_
28-15	4763-4764	.	_

29-1	4765-4770	Image	_
29-2	4771-4776	order	_
29-3	4777-4780	was	_
29-4	4781-4793	pseudorandom	_
29-5	4794-4800	within	_
29-6	4801-4805	each	_
29-7	4806-4811	block	_
29-8	4812-4813	,	_
29-9	4814-4817	and	_
29-10	4818-4824	images	_
29-11	4825-4829	were	_
29-12	4830-4839	presented	_
29-13	4840-4844	only	_
29-14	4845-4849	once	_
29-15	4850-4856	across	_
29-16	4857-4860	the	_
29-17	4861-4864	two	_
29-18	4865-4869	runs	_
29-19	4870-4871	.	_

30-1	4872-4881	Following	_
30-2	4882-4885	the	_
30-3	4886-4890	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
30-4	4891-4899	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
30-5	4900-4907	session	_
30-6	4908-4909	,	_
30-7	4910-4913	the	_
30-8	4914-4926	participants	_
30-9	4927-4936	completed	_
30-10	4937-4938	a	_
30-11	4939-4943	task	_
30-12	4944-4946	to	_
30-13	4947-4953	assess	_
30-14	4954-4959	image	_
30-15	4960-4971	recognition	_
30-16	4972-4975	and	_
30-17	4976-4982	ensure	_
30-18	4983-4987	that	_
30-19	4988-5000	participants	_
30-20	5001-5004	did	_
30-21	5005-5008	not	_
30-22	5009-5013	fall	_
30-23	5014-5020	asleep	_
30-24	5021-5027	during	_
30-25	5028-5033	image	_
30-26	5034-5046	presentation	_
30-27	5047-5048	.	_

31-1	5049-5053	Each	_
31-2	5054-5056	of	_
31-3	5057-5060	the	_
31-4	5061-5063	90	_
31-5	5064-5074	previously	_
31-6	5075-5084	presented	_
31-7	5085-5092	stimuli	_
31-8	5093-5094	,	_
31-9	5095-5100	along	_
31-10	5101-5105	with	_
31-11	5106-5108	90	_
31-12	5109-5110	(	_
31-13	5111-5113	30	_
31-14	5114-5117	per	_
31-15	5118-5127	condition	_
31-16	5128-5129	)	_
31-17	5130-5135	never	_
31-18	5136-5140	seen	_
31-19	5141-5148	stimuli	_
31-20	5149-5150	,	_
31-21	5151-5155	were	_
31-22	5156-5165	presented	_
31-23	5166-5174	randomly	_
31-24	5175-5177	on	_
31-25	5178-5179	a	_
31-26	5180-5188	computer	_
31-27	5189-5195	screen	_
31-28	5196-5197	.	_

32-1	5198-5204	Images	_
32-2	5205-5209	were	_
32-3	5210-5219	presented	_
32-4	5220-5223	for	_
32-5	5224-5226	an	_
32-6	5227-5236	unlimited	_
32-7	5237-5245	duration	_
32-8	5246-5247	,	_
32-9	5248-5253	until	_
32-10	5254-5255	a	_
32-11	5256-5259	key	_
32-12	5260-5263	was	_
32-13	5264-5271	pressed	_
32-14	5272-5274	to	_
32-15	5275-5283	indicate	_
32-16	5284-5291	whether	_
32-17	5292-5295	the	_
32-18	5296-5301	image	_
32-19	5302-5305	was	_
32-20	5306-5316	previously	_
32-21	5317-5321	seen	_
32-22	5322-5328	during	_
32-23	5329-5332	the	_
32-24	5333-5337	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
32-25	5338-5345	session	_
32-26	5346-5348	or	_
32-27	5349-5352	not	_
32-28	5353-5354	(	_
32-29	5355-5356	k	_
32-30	5357-5358	=	_
32-31	5359-5362	yes	_
32-32	5363-5364	;	_
32-33	5365-5366	l	_
32-34	5367-5368	=	_
32-35	5369-5371	no	_
32-36	5372-5373	)	_
32-37	5374-5375	.	_

33-1	5376-5379	The	_
33-2	5380-5386	number	_
33-3	5387-5389	of	_
33-4	5390-5394	hits	_
33-5	5395-5396	(	_
33-6	5397-5406	correctly	_
33-7	5407-5418	identifying	_
33-8	5419-5420	a	_
33-9	5421-5425	seen	_
33-10	5426-5431	image	_
33-11	5432-5433	)	_
33-12	5434-5437	and	_
33-13	5438-5443	false	_
33-14	5444-5450	alarms	_
33-15	5451-5452	(	_
33-16	5453-5464	incorrectly	_
33-17	5465-5476	identifying	_
33-18	5477-5479	an	_
33-19	5480-5486	unseen	_
33-20	5487-5492	image	_
33-21	5493-5495	as	_
33-22	5496-5500	seen	_
33-23	5501-5502	)	_
33-24	5503-5507	were	_
33-25	5508-5515	counted	_
33-26	5516-5519	for	_
33-27	5520-5524	each	_
33-28	5525-5533	stimulus	_
33-29	5534-5538	type	_
33-30	5539-5540	.	_

34-1	5541-5543	To	_
34-2	5544-5551	measure	_
34-3	5552-5563	recognition	_
34-4	5564-5565	,	_
34-5	5566-5567	a	_
34-6	5568-5579	sensitivity	_
34-7	5580-5585	index	_
34-8	5586-5587	(	_
34-9	5588-5590	dâ€²	_
34-10	5591-5592	=	_
34-11	5593-5598	Zhits	_
34-12	5599-5600	âˆ’	_
34-13	5601-5607	Zfalse	_
34-14	5608-5614	alarms	_
34-15	5615-5616	)	_
34-16	5617-5620	was	_
34-17	5621-5625	then	_
34-18	5626-5636	calculated	_
34-19	5637-5639	to	_
34-20	5640-5647	measure	_
34-21	5648-5651	the	_
34-22	5652-5659	ability	_
34-23	5660-5662	to	_
34-24	5663-5674	distinguish	_
34-25	5675-5682	between	_
34-26	5683-5687	seen	_
34-27	5688-5691	and	_
34-28	5692-5697	never	_
34-29	5698-5702	seen	_
34-30	5703-5709	images	_
34-31	5710-5711	.	_

35-1	5712-5715	The	_
35-2	5716-5722	effect	_
35-3	5723-5725	of	_
35-4	5726-5730	user	_
35-5	5731-5737	status	_
35-6	5738-5741	and	_
35-7	5742-5748	gender	_
35-8	5749-5751	on	_
35-9	5752-5763	sensitivity	_
35-10	5764-5767	was	_
35-11	5768-5776	examined	_
35-12	5777-5781	with	_
35-13	5782-5793	independent	_
35-14	5794-5801	samples	_
35-15	5802-5809	t-tests	_
35-16	5810-5811	.	_

36-1	5812-5817	Image	_
36-2	5818-5829	acquisition	_
36-3	5830-5833	and	_
36-4	5834-5842	analysis	_
36-5	5843-5851	Scanning	_
36-6	5852-5855	was	_
36-7	5856-5865	performed	_
36-8	5866-5871	using	_
36-9	5872-5873	a	_
36-10	5874-5881	3-Tesla	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
36-11	5882-5885	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
36-12	5886-5890	Trio	_
36-13	5891-5892	(	_
36-14	5893-5900	Siemens	_
36-15	5901-5908	Medical	_
36-16	5909-5910	,	_
36-17	5911-5919	Erlangen	_
36-18	5920-5921	,	_
36-19	5922-5929	Germany	_
36-20	5930-5931	)	_
36-21	5932-5933	.	_

37-1	5934-5949	High-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
37-2	5950-5961	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-3	5962-5972	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-4	5973-5979	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-5	5980-5984	were	_
37-6	5985-5990	first	_
37-7	5991-5999	acquired	_
37-8	6000-6003	and	_
37-9	6004-6008	used	_
37-10	6009-6015	during	_
37-11	6016-6031	co-registration	_
37-12	6032-6035	and	_
37-13	6036-6049	normalization	_
37-14	6050-6052	of	_
37-15	6053-6056	the	_
37-16	6057-6067	functional	_
37-17	6068-6073	scans	_
37-18	6074-6075	[	_
37-19	6076-6086	repetition	_
37-20	6087-6091	time	_
37-21	6092-6093	(	_
37-22	6094-6096	TR	_
37-23	6097-6098	)	_
37-24	6099-6100	=	_
37-25	6101-6105	1750	_
37-26	6106-6108	ms	_
37-27	6109-6110	,	_
37-28	6111-6115	echo	_
37-29	6116-6120	time	_
37-30	6121-6122	(	_
37-31	6123-6125	TE	_
37-32	6126-6127	)	_
37-33	6128-6129	=	_
37-34	6130-6131	4	_
37-35	6132-6134	ms	_
37-36	6135-6136	,	_
37-37	6137-6142	voxel	_
37-38	6143-6153	dimensions	_
37-39	6154-6157	1.0	_
37-40	6158-6159	Ã—	_
37-41	6160-6163	1.0	_
37-42	6164-6165	Ã—	_
37-43	6166-6169	1.0	_
37-44	6170-6172	mm	_
37-45	6173-6174	,	_
37-46	6175-6178	and	_
37-47	6179-6182	160	_
37-48	6183-6189	slices	_
37-49	6190-6191	]	_
37-50	6192-6193	.	_

38-1	6194-6204	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
38-2	6205-6210	scans	_
38-3	6211-6215	were	_
38-4	6216-6224	acquired	_
38-5	6225-6230	using	_
38-6	6231-6232	a	_
38-7	6233-6241	standard	_
38-8	6242-6252	multislice	_
38-9	6253-6264	single-shot	_
38-10	6265-6273	gradient	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
38-11	6274-6285	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
38-12	6286-6293	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
38-13	6294-6302	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
38-14	6303-6304	(	_
38-15	6305-6307	TR	_
38-16	6308-6309	=	_
38-17	6310-6314	2200	_
38-18	6315-6317	ms	_
38-19	6318-6319	,	_
38-20	6320-6322	TE	_
38-21	6323-6324	=	_
38-22	6325-6327	30	_
38-23	6328-6330	ms	_
38-24	6331-6332	,	_
38-25	6333-6338	voxel	_
38-26	6339-6349	dimensions	_
38-27	6350-6353	3.0	_
38-28	6354-6355	Ã—	_
38-29	6356-6359	3.0	_
38-30	6360-6361	Ã—	_
38-31	6362-6365	3.0	_
38-32	6366-6368	mm	_
38-33	6369-6370	,	_
38-34	6371-6374	and	_
38-35	6375-6377	64	_
38-36	6378-6379	Ã—	_
38-37	6380-6382	64	_
38-38	6383-6389	matrix	_
38-39	6390-6391	)	_
38-40	6392-6393	.	_

39-1	6394-6407	Preprocessing	_
39-2	6408-6411	and	_
39-3	6412-6417	whole	_
39-4	6418-6423	brain	_
39-5	6424-6429	image	_
39-6	6430-6438	analysis	_
39-7	6439-6443	were	_
39-8	6444-6453	conducted	_
39-9	6454-6458	with	_
39-10	6459-6463	SPM8	_
39-11	6464-6465	(	_
39-12	6466-6474	Wellcome	_
39-13	6475-6485	Department	_
39-14	6486-6488	of	_
39-15	6489-6498	Cognitive	_
39-16	6499-6508	Neurology	_
39-17	6509-6510	,	_
39-18	6511-6517	London	_
39-19	6518-6519	,	_
39-20	6520-6522	UK	_
39-21	6523-6524	)	_
39-22	6525-6526	,	_
39-23	6527-6538	implemented	_
39-24	6539-6541	in	_
39-25	6542-6548	Matlab	_
39-26	6549-6553	7.14	_
39-27	6554-6555	(	_
39-28	6556-6565	MathWorks	_
39-29	6566-6567	,	_
39-30	6568-6574	Natick	_
39-31	6575-6576	,	_
39-32	6577-6579	MA	_
39-33	6580-6581	)	_
39-34	6582-6583	.	_

40-1	6584-6597	Preprocessing	_
40-2	6598-6603	steps	_
40-3	6604-6607	are	_
40-4	6608-6610	as	_
40-5	6611-6618	follows	_
40-6	6619-6620	:	_
40-7	6621-6632	realignment	_
40-8	6633-6635	to	_
40-9	6636-6639	the	_
40-10	6640-6644	mean	_
40-11	6645-6650	image	_
40-12	6651-6652	,	_
40-13	6653-6668	co-registration	_
40-14	6669-6671	of	_
40-15	6672-6675	the	_
40-16	6676-6687	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-17	6688-6698	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-18	6699-6703	scan	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-19	6704-6707	and	_
40-20	6708-6711	the	_
40-21	6712-6716	mean	_
40-22	6717-6726	realigned	_
40-23	6727-6732	image	_
40-24	6733-6734	,	_
40-25	6735-6748	normalization	_
40-26	6749-6751	to	_
40-27	6752-6760	standard	_
40-28	6761-6766	space	_
40-29	6767-6768	(	_
40-30	6769-6777	Montreal	_
40-31	6778-6790	Neurological	_
40-32	6791-6800	Institute	_
40-33	6801-6809	template	_
40-34	6810-6811	)	_
40-35	6812-6813	,	_
40-36	6814-6817	and	_
40-37	6818-6827	smoothing	_
40-38	6828-6832	with	_
40-39	6833-6835	an	_
40-40	6836-6840	8-mm	_
40-41	6841-6849	Gaussian	_
40-42	6850-6856	kernel	_
40-43	6857-6858	.	_

41-1	6859-6869	Functional	_
41-2	6870-6876	images	_
41-3	6877-6881	were	_
41-4	6882-6889	modeled	_
41-5	6890-6894	with	_
41-6	6895-6896	a	_
41-7	6897-6903	boxcar	_
41-8	6904-6912	function	_
41-9	6913-6922	convolved	_
41-10	6923-6927	with	_
41-11	6928-6931	the	_
41-12	6932-6943	hemodynamic	_
41-13	6944-6952	response	_
41-14	6953-6961	function	_
41-15	6962-6966	over	_
41-16	6967-6971	task	_
41-17	6972-6978	blocks	_
41-18	6979-6980	(	_
41-19	6981-6989	positive	_
41-20	6990-6991	,	_
41-21	6992-7000	negative	_
41-22	7001-7002	,	_
41-23	7003-7006	and	_
41-24	7007-7014	neutral	_
41-25	7015-7021	images	_
41-26	7022-7023	)	_
41-27	7024-7029	using	_
41-28	7030-7033	the	_
41-29	7034-7041	general	_
41-30	7042-7048	linear	_
41-31	7049-7054	model	_
41-32	7055-7056	.	_

42-1	7057-7068	First-level	_
42-2	7069-7070	,	_
42-3	7071-7084	fixed-effects	_
42-4	7085-7094	contrasts	_
42-5	7095-7099	were	_
42-6	7100-7107	created	_
42-7	7108-7111	for	_
42-8	7112-7120	positive	_
42-9	7121-7122	>	_
42-10	7123-7130	neutral	_
42-11	7131-7134	and	_
42-12	7135-7143	negative	_
42-13	7144-7145	>	_
42-14	7146-7153	neutral	_
42-15	7154-7157	for	_
42-16	7158-7162	each	_
42-17	7163-7174	participant	_
42-18	7175-7176	.	_

43-1	7177-7188	Group-level	_
43-2	7189-7200	differences	_
43-3	7201-7202	(	_
43-4	7203-7207	user	_
43-5	7208-7214	status	_
43-6	7215-7216	)	_
43-7	7217-7221	were	_
43-8	7222-7232	calculated	_
43-9	7233-7238	using	_
43-10	7239-7251	second-level	_
43-11	7252-7253	,	_
43-12	7254-7268	random-effects	_
43-13	7269-7277	analyses	_
43-14	7278-7280	of	_
43-15	7281-7284	the	_
43-16	7285-7296	first-level	_
43-17	7297-7306	contrasts	_
43-18	7307-7310	for	_
43-19	7311-7314	the	_
43-20	7315-7321	entire	_
43-21	7322-7328	sample	_
43-22	7329-7330	(	_
43-23	7331-7338	primary	_
43-24	7339-7347	analysis	_
43-25	7348-7349	)	_
43-26	7350-7351	,	_
43-27	7352-7355	and	_
43-28	7356-7366	separately	_
43-29	7367-7370	for	_
43-30	7371-7374	men	_
43-31	7375-7378	and	_
43-32	7379-7384	women	_
43-33	7385-7386	(	_
43-34	7387-7396	secondary	_
43-35	7397-7405	analysis	_
43-36	7406-7407	)	_
43-37	7408-7409	.	_

44-1	7410-7413	The	_
44-2	7414-7421	primary	_
44-3	7422-7430	analysis	_
44-4	7431-7440	examining	_
44-5	7441-7444	the	_
44-6	7445-7451	effect	_
44-7	7452-7454	of	_
44-8	7455-7459	user	_
44-9	7460-7465	group	_
44-10	7466-7469	and	_
44-11	7470-7477	whether	_
44-12	7478-7483	group	_
44-13	7484-7490	status	_
44-14	7491-7505	differentially	_
44-15	7506-7514	affected	_
44-16	7515-7523	response	_
44-17	7524-7526	to	_
44-18	7527-7535	positive	_
44-19	7536-7539	and	_
44-20	7540-7548	negative	_
44-21	7549-7555	images	_
44-22	7556-7559	was	_
44-23	7560-7568	assessed	_
44-24	7569-7573	with	_
44-25	7574-7575	a	_
44-26	7576-7577	2	_
44-27	7578-7579	(	_
44-28	7580-7584	user	_
44-29	7585-7590	group	_
44-30	7591-7592	)	_
44-31	7593-7594	Ã—	_
44-32	7595-7596	2	_
44-33	7597-7598	(	_
44-34	7599-7606	valence	_
44-35	7607-7608	)	_
44-36	7609-7617	analysis	_
44-37	7618-7620	of	_
44-38	7621-7629	variance	_
44-39	7630-7631	(	_
44-40	7632-7637	ANOVA	_
44-41	7638-7639	)	_
44-42	7640-7641	.	_

45-1	7642-7649	T-tests	_
45-2	7650-7657	further	_
45-3	7658-7666	examined	_
45-4	7667-7670	the	_
45-5	7671-7683	differential	_
45-6	7684-7692	response	_
45-7	7693-7698	among	_
45-8	7699-7706	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
45-9	7707-7712	users	_
45-10	7713-7716	and	_
45-11	7717-7725	controls	_
45-12	7726-7729	for	_
45-13	7730-7738	positive	_
45-14	7739-7742	and	_
45-15	7743-7751	negative	_
45-16	7752-7758	images	_
45-17	7759-7760	.	_

46-1	7761-7773	Gender-based	_
46-2	7774-7782	analyses	_
46-3	7783-7787	were	_
46-4	7788-7797	conducted	_
46-5	7798-7802	with	_
46-6	7803-7813	one-sample	_
46-7	7814-7815	(	_
46-8	7816-7822	within	_
46-9	7823-7828	group	_
46-10	7829-7830	)	_
46-11	7831-7834	and	_
46-12	7835-7845	two-sample	_
46-13	7846-7847	(	_
46-14	7848-7855	between	_
46-15	7856-7861	group	_
46-16	7862-7863	)	_
46-17	7864-7871	t-tests	_
46-18	7872-7873	.	_

47-1	7874-7877	The	_
47-2	7878-7889	examination	_
47-3	7890-7892	of	_
47-4	7893-7902	potential	_
47-5	7903-7915	contributing	_
47-6	7916-7923	factors	_
47-7	7924-7927	was	_
47-8	7928-7937	conducted	_
47-9	7938-7940	by	_
47-10	7941-7947	adding	_
47-11	7948-7958	covariates	_
47-12	7959-7960	(	_
47-13	7961-7971	depression	_
47-14	7972-7986	symptomatology	_
47-15	7987-7988	,	_
47-16	7989-7998	education	_
47-17	7999-8000	,	_
47-18	8001-8006	state	_
47-19	8007-8014	anxiety	_
47-20	8015-8016	,	_
47-21	8017-8020	and	_
47-22	8021-8031	cigarettes	_
47-23	8032-8035	per	_
47-24	8036-8039	day	_
47-25	8040-8041	)	_
47-26	8042-8044	to	_
47-27	8045-8048	the	_
47-28	8049-8054	model	_
47-29	8055-8057	or	_
47-30	8058-8066	directly	_
47-31	8067-8076	comparing	_
47-32	8077-8083	groups	_
47-33	8084-8085	(	_
47-34	8086-8095	marijuana	_
47-35	8096-8106	dependence	_
47-36	8107-8108	)	_
47-37	8109-8110	.	_

48-1	8111-8114	All	_
48-2	8115-8123	reported	_
48-3	8124-8131	results	_
48-4	8132-8135	met	_
48-5	8136-8148	significance	_
48-6	8149-8151	at	_
48-7	8152-8153	p	_
48-8	8154-8155	<	_
48-9	8156-8159	.05	_
48-10	8160-8169	corrected	_
48-11	8170-8173	for	_
48-12	8174-8182	multiple	_
48-13	8183-8194	comparisons	_
48-14	8195-8196	(	_
48-15	8197-8207	determined	_
48-16	8208-8210	by	_
48-17	8211-8216	Monte	_
48-18	8217-8222	Carlo	_
48-19	8223-8233	simulation	_
48-20	8234-8235	;	_
48-21	8236-8247	voxel-level	_
48-22	8248-8257	threshold	_
48-23	8258-8260	of	_
48-24	8261-8262	p	_
48-25	8263-8264	<	_
48-26	8265-8269	.005	_
48-27	8270-8273	for	_
48-28	8274-8276	at	_
48-29	8277-8282	least	_
48-30	8283-8285	48	_
48-31	8286-8296	contiguous	_
48-32	8297-8303	voxels	_
48-33	8304-8305	;	_
48-34	8306-8314	AlphaSim	_
48-35	8315-8317	in	_
48-36	8318-8322	REST	_
48-37	8323-8330	toolbox	_
48-38	8331-8332	)	_
48-39	8333-8334	.	_

